A conversation with Enveric Biosciences CEO Joseph Tucker, Ph.D.
Two themes have arisen as of late in the clinical trials space, and both collide in this Q&A for an interesting perspective on pursuing regulatory approval of hallucinogenic and non-hallucinogenic psychedelic therapies in the U.S. and abroad, namely in Australia. Herein, Enveric Biosciences CEO Joseph Tucker, Ph.D., chronicles Enveric’s quest for regulatory approval by first heading down under, as well as addresses both the confusion and excitement experienced by those navigating the unknowns of developing psychedelics for therapeutic use. Enveric’s pipeline includes both hallucinogenic and non-hallucinogenic small molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. EB-373, its leading candidate and next-generation synthetic prodrug of the active metabolite, psilocin, is on track for a Phase 1 clinical trial in early 2024.
